The Magnitude of Carbapenemase and ESBL Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections at Tikur Anbessa Specialized Teaching Hospital, Addis Ababa, Ethiopia.
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
Carbapenem-Resistant Enterobacteriaceae
/ isolation & purification
Cross-Sectional Studies
Drug Resistance, Multiple, Bacterial
Escherichia coli
/ isolation & purification
Ethiopia
/ epidemiology
Hospitals, Teaching
Humans
Microbial Sensitivity Tests
Urinary Tract Infections
/ epidemiology
beta-Lactamases
Carbapenemase
Enterobacteriaceae
Extended-spectrum-beta-lactamase
Multidrug-resistant
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
17
12
2021
medline:
7
5
2022
entrez:
16
12
2021
Statut:
ppublish
Résumé
The emergence of multidrug-resistant organisms, such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE), and carbapenemase-producing Enterobacteriaceae (CPE) is a public health concern. Therefore, this study aimed to determine the magnitude of carbapenemase and ESBL producing bacteria isolated from patients affected by Urinary Tract Infection (UTI). A cross-sectional study was conducted from December 2018 to March 2019 at Tikur Anbessa Specialized Hospital. A total of 120 Enterobacteriaceae isolates from UTI patients were collected and identified on species level using standard microbiological methods. Antimicrobial susceptibility test was determined according to the guidelines of the Clinical and Laboratory Standards Institute. Detection of ESBL production was carried out by using ESBL ChromoSelect Agar medium and the combined disk diffusion. Production of carbapenemase was determined by using Hodge-test and modified carbapenem inactivation method as described in CLSI guidelines. Out of the total 120 Enterobacteriaceae isolates, 74 (61.7%) were ESBL-producers, and 8 (6.7%) were carbapenemase producers. The most common ESBL producing isolate was E.coli 38 (51.4%) and the most common carbapenemase-producing isolate was K.pneumoniae five (62.5%). Most of the ESBL and carbapenemase-producing isolates were recovered from hospitalized patients 46 (62.2%) and 7 (87.5%) respectively. The rate of ESBL and CPE production was observed high among patients taking antibiotics 64.8% (59/91) and 7.7% (7/91) respectively, but no significant association was observed p > 0.05. Furthermore, about 1.7% (2/120) isolates were found both ESBL and carbapenemase producers. Significant resistances rates were observed in ESBL and CPE isolates. Enterobacteriaceae isolates showed a significantly higher rate of ESBL production. A significant figure of carbapenemase production was observed among Enterobacteriaceae isolates causing UTI. The production of ESBL and CPE enhanced for an increased rate of MDR patterns. Efforts need to be made to introduce a system for tracking and detecting ESBL-PE and CPE-producing bacteria in hospitals, and monitoring dissemination of ESBL and CPE-producing Enterobacteriaceae is strongly recommended.
Sections du résumé
BACKGROUND
BACKGROUND
The emergence of multidrug-resistant organisms, such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE), and carbapenemase-producing Enterobacteriaceae (CPE) is a public health concern. Therefore, this study aimed to determine the magnitude of carbapenemase and ESBL producing bacteria isolated from patients affected by Urinary Tract Infection (UTI).
METHODS
METHODS
A cross-sectional study was conducted from December 2018 to March 2019 at Tikur Anbessa Specialized Hospital. A total of 120 Enterobacteriaceae isolates from UTI patients were collected and identified on species level using standard microbiological methods. Antimicrobial susceptibility test was determined according to the guidelines of the Clinical and Laboratory Standards Institute. Detection of ESBL production was carried out by using ESBL ChromoSelect Agar medium and the combined disk diffusion. Production of carbapenemase was determined by using Hodge-test and modified carbapenem inactivation method as described in CLSI guidelines.
RESULTS
RESULTS
Out of the total 120 Enterobacteriaceae isolates, 74 (61.7%) were ESBL-producers, and 8 (6.7%) were carbapenemase producers. The most common ESBL producing isolate was E.coli 38 (51.4%) and the most common carbapenemase-producing isolate was K.pneumoniae five (62.5%). Most of the ESBL and carbapenemase-producing isolates were recovered from hospitalized patients 46 (62.2%) and 7 (87.5%) respectively. The rate of ESBL and CPE production was observed high among patients taking antibiotics 64.8% (59/91) and 7.7% (7/91) respectively, but no significant association was observed p > 0.05. Furthermore, about 1.7% (2/120) isolates were found both ESBL and carbapenemase producers. Significant resistances rates were observed in ESBL and CPE isolates.
CONCLUSION
CONCLUSIONS
Enterobacteriaceae isolates showed a significantly higher rate of ESBL production. A significant figure of carbapenemase production was observed among Enterobacteriaceae isolates causing UTI. The production of ESBL and CPE enhanced for an increased rate of MDR patterns. Efforts need to be made to introduce a system for tracking and detecting ESBL-PE and CPE-producing bacteria in hospitals, and monitoring dissemination of ESBL and CPE-producing Enterobacteriaceae is strongly recommended.
Identifiants
pubmed: 34914083
doi: 10.1007/5584_2021_687
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-128Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Abayneh M, Tesfaw G, Abdissa A (2018) Isolation of extended-spectrum β-lactamase-(ESBL-) producing Escherichia coli and Klebsiella pneumoniae from patients with community-onset urinary tract infections in Jimma University Specialized Hospital, Southwest Ethiopia. Can J Infect Dis Med Microbiol 2018:4846159
doi: 10.1155/2018/4846159
Albaramki J, Abdelghani T, Dalaeen A, Khdair Ahmad F, Alassaf A, Odeh R (2019) Urinary tract infection caused by ESBL-producing bacteria: risk factors and antibiotic resistance. Pediatr Int 61(11):1127–1132
doi: 10.1111/ped.13911
Amladi AU, Abirami B, Devi SM, Sudarsanam TD, Kandasamy S, Kekre N, Veeraraghavan B, Sahni RD (2019) Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. Indian J Med Res 149:185
doi: 10.4103/ijmr.IJMR_2086_17
Behzadi P, Urbán E, Matuz M, Benkő R, Gajdács M (2021) The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol 1323:35–69
doi: 10.1007/5584_2020_566
Bharadwaj R, Robinson ML, Balasubramanian U, Kulkarni V, Kagal A, Raichur P, Khadse S, Kadam D, Valvi C, Kinikar A (2018) Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India. BMC Infect Dis 18:504
doi: 10.1186/s12879-018-3390-4
Chander A, Shrestha CD (2013) Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes 6:487
doi: 10.1186/1756-0500-6-487
CLSI (2017) Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne
CLSI (2018) Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 28th edn. Clinical and Laboratory Standards Institute, Wayne
David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G (2019) Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 4:1919–1929
doi: 10.1038/s41564-019-0492-8
Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D (2013) Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr 163:1417–1421
doi: 10.1016/j.jpeds.2013.06.078
De La Blanchardière A, Dargère S, Guérin F, Daurel C, Saint-Lorant G, Verdon R, Cattoir V (2015) Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. Med Mal Infect 45:169–172
doi: 10.1016/j.medmal.2015.03.003
Eshetie S, Unakal C, Gelaw A, Ayelign B, Endris M, Moges F (2015) Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral hospital, Northwest Ethiopia. Antimicrob Resist Infect Control 4:12
doi: 10.1186/s13756-015-0054-7
Fernando M, Luke W, Miththinda J, Wickramasinghe R, Sebastiampillai B, Gunathilake M, Silva F, Premaratna R (2017) Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern – a hospital based cross sectional study. BMC Infect Dis 17:138
doi: 10.1186/s12879-017-2250-y
Flateau C, Duron-Martinaud S, Haus-Cheymol R, Bousquet A, Delaune D, Ficko C, Merens A, Rapp C (2018) Prevalence and risk factors for extended-spectrum beta-lactamase-producing-Enterobacteriaceae in French military and civilian travelers: a cross-sectional analysis. Travel Med Infect Dis 23:44–48
doi: 10.1016/j.tmaid.2018.03.009
Flokas ME, Karanika S, Alevizakos M, Mylonakis E (2017) Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: a systematic review and meta-analysis. PLoS One 12:e0171216
doi: 10.1371/journal.pone.0171216
Gajdács M (2019) The concept of an ideal antibiotic: implications for drug design. Molecules 24:892
doi: 10.3390/molecules24050892
Gajdács M (2020) The importance of reporting clinical and epidemiological data in urology: local experiences and insights from the international literature. Medicina 56:581
doi: 10.3390/medicina56110581
Gajdács M, Ábrók M, Lázár A, Burián K (2019) Comparative epidemiology and resistance trends of common urinary pathogens in a tertiary-care hospital: a 10-year surveillance study. Medicina 55:356
doi: 10.3390/medicina55070356
Gajdács M, Ábrók M, Lázár A, Jánvári L, Tóth Á, Terhes G, Burián K (2020a) Detection of VIM, NDM and OXA-48 producing carbapenem resistant Enterobacterales among clinical isolates in southern Hungary. Acta Microbiol Immunol Hung 67:209–215
doi: 10.1556/030.2020.01181
Gajdács M, Bátori Z, Ábrók M, Lázár A, Burián K (2020b) Characterization of resistance in gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis. Life 10:16
doi: 10.3390/life10020016
Gashaw M, Berhane M, Bekele S, Kibru G, Teshager L, Yilma Y, Ahmed Y, Fentahun N, Assefa H, Wieser A (2018) Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrob Resist Infecti Control 7:138
doi: 10.1186/s13756-018-0431-0
Hassan H, Abdalhamid B (2014) Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. J Infect Dev Ctries 8:282–288
doi: 10.3855/jidc.3809
Kiddee A, Assawatheptawee K, Na-Udom A, Boonsawang P, Treebupachatsakul P, Walsh TR, Niumsup PR (2019) Risk factors for extended-spectrum β-lactamase-producing Enterobacteriaceae carriage in patients admitted to intensive care unit in a tertiary care hospital in Thailand. Microb Drug Resist 25:1182–1190
doi: 10.1089/mdr.2018.0318
Legese MH, Weldearegay GM, Asrat D (2017) Extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae among Ethiopian children. Infect Drug Resist 10:27
doi: 10.2147/IDR.S127177
Nakai H, Hagihara M, Kato H, Hirai J, Nishiyama N, Koizumi Y, Sakanashi D, Suematsu H, Yamagishi Y, Mikamo H (2016) Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. J Infect Chemother 22:319–326
doi: 10.1016/j.jiac.2016.02.004
Okoche D, Asiimwe BB, Katabazi FA, Kato L, Najjuka CF (2015) Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS One 10:e0135745
doi: 10.1371/journal.pone.0135745
Ouedraogo AS, Sanou M, Kissou A, Sanou S, Solare H, Kabore F, Poda A, Aberkane S, Bouzinbi N, Sano I, Nacro B, Sangare L, Carriere C, Decre D, Ouegraogo R, Jean-Pierre H, Godreuil S (2016) High prevalence of extended-spectrum ss-lactamase producing enterobacteriaceae among clinical isolates in Burkina Faso. BMC Infect Dis 16:326
doi: 10.1186/s12879-016-1655-3
Pishtiwan AH, Khadija KM (2019) Prevalence of blaTEM, blaSHV, and blaCTX-M genes among ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from thalassemia patients in Erbil, , Iraq. Mediterr J Hematol Infect Dis 11:e2019041
doi: 10.4084/mjhid.2019.041
Rao MR, Chandrashaker P, Mahale RP, Shivappa SG, Gowda RS, Chitharagi VB (2019) Detection of carbapenemase production in Enterobacteriaceae and pseudomonas species by carbapenemase Nordmann–Poirel test. J Lab Phys 11:107
Reuland E, Al Naiemi N, Kaiser A, Heck M, Kluytmans J, Savelkoul P, Elders P, Vandenbroucke-Grauls C (2016) Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother 71:1076–1082
doi: 10.1093/jac/dkv441
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing. Enterobacteriaceae CMR 31(2):e00079–e00017
Saliu EM, Vahjen W, Zentek J (2017) Types and prevalence of extended-spectrum beta-lactamase producing Enterobacteriaceae in poultry. Anim Health Res Rev 18:46–57
doi: 10.1017/S1466252317000020
Selassie LG (2016) Prevalence of extended spectrum beta-lactamase producing Enterobacteriaceae: a cross sectional study at Adama Hospital, Adama, Ethiopia. J Emerg Infect Dis 1:102
Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B (2016) Prevalence of ESBL in Escherichia coli isolates among ICU patients in a tertiary care hospital. J Clin Diagn Res 10:DC19–DC22
pubmed: 27790433
pmcid: 5071933
Tamadonfar KO, Omattage NS, Spaulding CN, Hultgren SJ (2019) Reaching the end of the line: urinary tract infections. Bacteria Intracellularity 7(3): 83–99
Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD (2019) Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia. Antimicrob Resist Infect Control 8:39
doi: 10.1186/s13756-019-0488-4
Vandepitte J, Verhaegen J, Engbaek K, Rohner P, Piot P, Heuck C, Heuck C (2003) Basic laboratory procedures in clinical bacteriology. World Health Organization, Geneva
Woodford N, Xu-Mccrae L, Mushtaq S, Wu HHT, Ellington MJ, Lancaster O, Davies F, Donaldson H, Rao GG, Verma A (2018) Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK). J Antimicrob Chemother 73:698–702
doi: 10.1093/jac/dkx471